Abstract
Reducing the workload of the beta cell by inhibiting insulin secretion may provide beneficial effects for patients with type 2 diabetes. The aim of this study was to investigate the effect of NN414, a beta cell selective potassium channel opener in patients with type 2 diabetes. 24 patients were treated for seven days (placebo, 1.5, 4.5, and 10 mg/kg). In accordance with the pharmacological profile a significant and selective inhibition of insulin secretion was observed (1 h post dose). There were no statistically significant effects on overall glycaemic control. Based on OGTT derived parameters a borderline significant improvement in beta-cell function (1st and 2nd phase insulin secretion) was observed from Day 1 to Day 7.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
ATP-Binding Cassette Transporters / agonists*
-
ATP-Binding Cassette Transporters / metabolism
-
Aged
-
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage*
-
Cyclic S-Oxides / administration & dosage*
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / metabolism*
-
Double-Blind Method
-
Female
-
Humans
-
Insulin / metabolism*
-
Insulin Secretion
-
Insulin-Secreting Cells / metabolism*
-
Male
-
Middle Aged
-
Potassium Channels / agonists*
-
Potassium Channels / metabolism
-
Potassium Channels, Inwardly Rectifying / agonists*
-
Potassium Channels, Inwardly Rectifying / metabolism
-
Receptors, Drug / agonists*
-
Receptors, Drug / metabolism
-
Sulfonylurea Receptors
-
Time Factors
Substances
-
ABCC8 protein, human
-
ATP-Binding Cassette Transporters
-
Bridged Bicyclo Compounds, Heterocyclic
-
Cyclic S-Oxides
-
Insulin
-
NN 414
-
Potassium Channels
-
Potassium Channels, Inwardly Rectifying
-
Receptors, Drug
-
Sulfonylurea Receptors